Abstract
Accumulating evidence suggests that a dysregulation of the glutamatergic system exists in the brains of schizophrenia patients. The metabotropic glutamate (mGlu) receptors are being investigated as novel drug targets for this disease, and have shown promise in both preclinical and clinical studies. Activation of mGlu5 receptors may be efficacious for several symptom domains (positive, negative, and cognitive) and the potential for targeting mGlu5 receptors has been bolstered by recent research on mitigating toxicity profiles associated with mGlu5 activation. Additionally, genetic profiling of schizophrenia patients suggests that genes encoding for mGlu1 and mGlu3 receptors are altered, prompting preclinical studies that have demonstrated potential antipsychotic and cognitive enhancing effects of agents that activate mGlu1 and mGlu3 receptors, respectively. Development of subtype-specific drugs for the mGlu receptors, such as allosteric modulators, could provide a path forward for more efficacious and tolerable therapeutics for schizophrenia.
Citations
Dec 6, 2019·Nature Communications·Chris H HabrianEhud Y Isacoff
May 26, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Réjane TroudetStéphane Jamain
Jan 24, 2019·Frontiers in Cellular Neuroscience·Marco BocchioMarco Capogna
Sep 25, 2019·Evolution, Medicine, and Public Health·Bernard J Crespi
May 9, 2019·Pharmacology Research & Perspectives·Tyler W McCullock, Paul J Kammermeier
Dec 20, 2018·Frontiers in Molecular Neuroscience·Francesco MatriscianoAlessandro Guidotti
Mar 21, 2019·Frontiers in Psychiatry·Ferdinando NicolettiValeria Bruno
Nov 17, 2020·Frontiers in Cell and Developmental Biology·Carolina GubertAnthony J Hannan
Oct 17, 2018·Neuropharmacology·Max E JoffeP Jeffrey Conn
Dec 1, 2019·Neuron·Amanda Acosta-RuizJoshua Levitz
Feb 19, 2021·Translational Psychiatry·Giada MascioFerdinando Nicoletti
Apr 30, 2021·Frontiers in Neuroscience·Qiongqiong WuRenrong Wu
Jun 17, 2020·Current Drug Targets·Hemen S Ved, Gaurav M Doshi
May 25, 2018·ACS Chemical Neuroscience·Max E JoffeP Jeffrey Conn
Apr 8, 2020·ACS Pharmacology & Translational Science·Karen J GregoryColleen M Niswender
Jun 26, 2018·Journal of Medicinal Chemistry·Liang TanJianjun Cheng
Aug 31, 2021·Bioorganic & Medicinal Chemistry Letters·Yousuke YamadaBruce J Melancon
Aug 7, 2021·British Journal of Pharmacology·Caroline S CopelandThomas E Salt
Sep 18, 2021·The International Journal of Neuropsychopharmacology·Mai WatanabeShigeyuki Chaki